Autophagy-enhanced hybrid pyroptotic vesicles as personalized vaccines for cancer immunotherapy

Area of Science:

• Biomedical Engineering
• Immunology
• Nanotechnology

Background:

• Conventional tumor vaccines face limitations including poor antigen immunogenicity, inefficient lymph node accumulation, and inadequate antigen presentation by antigen-presenting cells (APCs).
• Pyroptosis, a pro-inflammatory cell death, can enhance immunogenicity, while autophagy promotes antigen presentation in APCs, offering potential solutions to vaccine limitations.

Purpose of the Study:

• To develop a biomimetic hybrid nanovaccine (hDMVac) leveraging pyroptosis and autophagy to overcome the limitations of traditional tumor vaccines.
• To evaluate the efficacy of hDMVac in enhancing antigen immunogenicity, APC maturation, and anti-tumor immune responses.

Main Methods:

• A hybrid nanovaccine (hDMVac) was constructed using pyroptotic tumor cells and dendritic cells (DCs), loaded with beclin-1.
• The nanovaccine's physicochemical properties, lymph node accumulation, and immune-stimulatory effects were characterized.
• In vivo efficacy was assessed in prophylactic and therapeutic melanoma models.

Main Results:

• hDMVac demonstrated optimal particle size (~160 nm) and enhanced accumulation in lymph nodes.
• The nanovaccine significantly improved antigen immunogenicity and induced autophagy in DCs, promoting DC maturation and antigen cross-presentation.
• hDMVac treatment led to robust antigen-specific T cell activation and effective suppression of tumor growth.

Conclusions:

• The developed hDMVac synergistically combines pyroptosis and autophagy to enhance anti-tumor immunity, addressing key limitations of current tumor vaccines.
• This dual-strategy nanovaccine presents a clinically translatable platform for improved cancer immunotherapy, compatible with existing treatment modalities.